{"id":987160,"date":"2026-07-30T07:35:45","date_gmt":"2026-07-30T11:35:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-07-30T07:35:45","modified_gmt":"2026-07-30T11:35:45","slug":"wave-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-reports-second-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n Dosing underway in\u00a0<\/em>
\n Phase 2a <\/em>
\n multidose portion <\/em>
\n of the INLIGHT<\/em>
\n
\n TM<\/em>
\n <\/sup>
\n trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg\/m<\/em>
\n
\n 2<\/em>
\n <\/sup>
\n ) and comorbidities;<\/em>
\n trial will also inform WVE-007’s potential <\/em>
\n in MASH, type 2 diabetes, and other cardiometabolic diseases<\/em>\n <\/p>\n

\n Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026<\/em>\n <\/p>\n

\n FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing); data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATD<\/em>\n <\/p>\n

\n CTA submission for WVE-008 for PNPLA3 liver disease (GalNAc-RNA editing) on track for 2H 2026<\/em>\n <\/p>\n

\n Well capitalized with cash, cash equivalents, and marketable securities of\u00a0$490.6 million\u00a0as of\u00a0June 30, 2026 and expected cash runway into 3Q 2028<\/em>\n <\/p>\n

\n Investor conference call and webcast at 8:30 a.m. ET today<\/em>\n <\/p>\n

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.<\/p>\n

\u201cOur second quarter performance reflects disciplined execution across the pipeline,\u201d said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. \u201cWe recently initiated dosing in the Phase 2a portion of our INLIGHT trial in obesity. Our Phase 1 clinical data have already demonstrated substantial reductions of fat \u2013 particularly harmful visceral fat \u2013 without muscle loss, and with the potential for once or twice-yearly dosing. We expect the Phase 2a portion of the INLIGHT trial, in individuals with higher BMI and higher body fat, to demonstrate WVE-007’s broad potential to deliver even greater fat loss and improvements in body composition, as well as benefits across additional cardiometabolic biomarkers such as liver fat. In tandem with this progress, we are working expeditiously to initiate Phase 2 trials evaluating WVE-007 in combination with incretins and as post-incretin maintenance; we believe WVE-007 has the potential to transform the current obesity treatment landscape.\u201d<\/p>\n

Dr. Bolno added, \u201cIn RNA editing, our RestorAATion-2 clinical data support WVE-006\u2019s potential to offer a new standard of care for individuals living with AATD by treating both lung and liver manifestations of the disease, and restoring dynamic response of AAT protein, with convenient, infrequent subcutaneous dosing, and without the risks associated with DNA editing. We look forward to meeting with the FDA to discuss a pathway for accelerated approval for WVE-006. Building on our clinical success in RNA editing, WVE-008, our PNPLA3 RNA editing program, has the potential to address the nine million individuals living with this genetic liver disease. It\u2019s exciting to see the clinical translation of our RNAi and RNA editing programs, enabled by our unique and proprietary chemistry, and supported by human genetics. We expect to provide further updates on our pipeline and platform innovations at our annual investor day this fall.\u201d<\/p>\n

\n Recent Business Highlights and Expected Milestones<\/strong>\n <\/p>\n

\n Obesity<\/em>\n <\/p>\n